Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers, Bluebird Submit Biologics License Application for Idecabtagene Vicleucel

share with twitter share with LinkedIn share with facebook
share via e-mail
03/31/2020 | 07:36am EDT

By Michael Dabaie

 

Bristol Myers Squibb and bluebird bio Inc. said they submitted their biologics license application to the U.S. Food and Drug Administration for idecabtagene vicleucel.

Idecabtagene vicleucel is the companies' lead investigational immunotherapy for the treatment of adult patients with multiple myeloma who have received at least three prior therapies.

The submission is based on results from the pivotal Phase 2 KarMMa study. Topline data from the study, reported in December, indicated the study met its primary endpoint of overall response rate, and the key secondary endpoint of complete response rate.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
BLUEBIRD BIO, INC. 4.64% 63.63 Delayed Quote.-27.49%
BRISTOL-MYERS SQUIBB COMPANY -0.15% 59.72 Delayed Quote.-6.96%
THE LEAD CO., INC. -2.37% 412 End-of-day quote.5.64%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BRISTOL-MYERS SQUIBB COMPA
05/29BRISTOL MYERS SQUIBB : to Hold Virtual Three-Part Investor Series
BU
05/28BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia for the..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
AQ
05/27BRISTOL MYERS SQUIBB : Gets European Union Approval for MS Drug Zeposia
DJ
05/27BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia (ozanim..
BU
05/26BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo® (nivol..
BU
05/25BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb'..
AQ
05/22Bristol Myers Says EMA Validates Applications for Idecabtagene Vicleucel, CC-..
DJ
05/22BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb'..
BU
More news
Financials (USD)
Sales 2020 41 932 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 322 M - -
P/E ratio 2020 114x
Yield 2020 2,99%
Capitalization 135 B 135 B -
EV / Sales 2019
EV / Sales 2020 3,87x
Nbr of Employees 30 000
Free-Float 77,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 67,34 $
Last Close Price 59,72 $
Spread / Highest target 39,0%
Spread / Average Target 12,8%
Spread / Lowest Target -89,7%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.96%135 128
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274